A proposal from the liver forum for the management of comorbidities in non-alcoholic steatohepatitis therapeutic trials-Reference-Cited by-同舟云学术

A proposal from the liver forum for the management of comorbidities in non-alcoholic steatohepatitis therapeutic trials

Published:2023-09 Issue:3 Volume:79 Page:829-841
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Pais Raluca^ORCID,Cariou Bertrand^ORCID,Noureddin Mazen,Francque Sven^ORCID,Schattenberg Jörn M.,Abdelmalek Manal F.^ORCID,Lalazar Gadi,Varma Sharat^ORCID,Dietrich Julie^ORCID,Miller Veronica^ORCID,Sanyal Arun,Ratziu Vlad

Publisher

Elsevier BV

Subject

Hepatology

Reference124 articles.

1. Nonalcoholic fatty liver disease as a metabolic disease in humans: a literature review;Cariou;Diabetes Obes Metab,2021

2. Baseline parameters in clinical trials for nonalcoholic steatohepatitis: recommendations from the liver Forum;Patel;Gastroenterology,2017

3. Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science;Siddiqui;Hepatology,2018

4. Defining improvement in nonalcoholic steatohepatitis for treatment trial endpoints: recommendations from the liver Forum;Cheung;Hepatology,2019

5. Factors to consider in development of drugs for pediatric nonalcoholic fatty liver disease;Vos;Gastroenterology,2019

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD);Journal of Hepatology;2024-09

2. Interleukin-mediated therapies in liver diseases and comorbidity effects;World Journal of Hepatology;2024-07-27

3. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis;New England Journal of Medicine;2024-07-25

4. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis;New England Journal of Medicine;2024-02-08

5. Therapeutic management of metabolic dysfunction associated steatotic liver disease;United European Gastroenterology Journal;2024-01-09